pSivida spins off nanotech diagnostics company
This article was originally published in Clinica
Executive Summary
Australian nanotechnology company pSivida has created a new subsidiary, AION Diagnostics, which will focus on developing products from the company's BioSilicon platform technology. The spin-off, funded through a private investment of Aus$1.2m ($0.85m) by pSivida, will enable the Perth-based company to focus on other core areas such as slow release drug delivery and brachytherapy.